On Friday, Johnson & Johnson JNJ announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-65.
The decision to discontinue this study is part of a strategic reprioritization of the company’s Communicable Diseases research and development (R&D) portfolio. No safety issues were identified.
Efficacy data from the Phase 2 field study will be available once the final data analyses, which are now underway, are complete.
Mosnodenvir (formerly JNJ-1802) was shown to be safe and well tolerated in previous Phase 1 and Phase 2a clinical studies.
In October 2023, results from the Phase 2a human challenge study found that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo.
The study evaluated different dosing regimens – low, medium or high – of JNJ-1802 against an attenuated dengue 3 serotype (DENV-3) in healthy adults.
All participants received daily doses of JNJ-1802 or a placebo over 26 days, during which they were challenged with DENV-3 on day 5.
All participants were monitored over 85 days. The study found a dose-dependent antiviral effect on the detectability of DENV-3 RNA and time to first onset of detectable DENV-3 RNA compared to placebo and was safe and well-tolerated.
In May, Takeda Pharmaceutical Co Ltd’s TAK dengue vaccine received World Health Organization’s (WHO) prequalification.
TAK-003 is the second dengue vaccine to be prequalified by WHO.
WHO recommended using TAK-003 in children aged 6–16 in settings with high dengue burden and transmission intensity.
Price Action: JNJ stock is down 0.60% at $159.53 at the last check on Friday.
Read Next:
Photo via Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
